Pulmonary Pipeline
Breathe Biologics is advancing JadiCell™ through a pulmonary-focused development strategy spanning late-stage ARDS development, a COPD development pathway, and carefully selected areas of potential future investigation.
A Multi-Indication Respiratory Development Strategy
JadiCell™ is being developed as an investigational regenerative immunology platform for severe pulmonary diseases characterized by inflammatory injury, immune dysregulation, endothelial and epithelial dysfunction, and maladaptive tissue remodeling.
The current strategy prioritizes Acute Respiratory Distress Syndrome (ARDS) as the lead late-stage program and Chronic Obstructive Pulmonary Disease (COPD) as a continued development pathway.
Additional pulmonary disease areas shown on this page are identified only as potential future indications and should not be interpreted as active clinical programs.
A Multi-Indication Respiratory Pipeline
JadiCell™ is being advanced through a pulmonary-focused strategy centered on ARDS, COPD, and selected areas of potential future investigation.
Lead late-stage clinical development program.
Continued development pathway in chronic obstructive pulmonary disease.
Not presented as an active clinical program.
Not presented as an active clinical program.
Not presented as an active clinical program.
Acute Respiratory Distress Syndrome
ARDS represents the lead clinical-development indication within the JadiCell™ pulmonary platform.
ARDS
Acute Respiratory Distress Syndrome is characterized by severe inflammatory lung injury, disruption of the alveolar-capillary barrier, pulmonary edema, impaired oxygenation, and respiratory failure.
JadiCell™ is being evaluated through a registered Phase 3 development program in ARDS.
Published Phase 1/2a research in COVID-19-associated ARDS provides human clinical and biomarker observations supporting continued investigation.
Severe Inflammatory Lung Injury
The development rationale centers on immune dysregulation, inflammatory cytokine signaling, endothelial dysfunction, epithelial injury, alveolar-capillary barrier disruption, and impaired tissue recovery.
Future conclusions regarding safety and efficacy require appropriately controlled clinical evaluation.
Chronic Obstructive Pulmonary Disease
COPD represents an additional pulmonary development pathway for the JadiCell™ platform.
COPD
Chronic Obstructive Pulmonary Disease is characterized by persistent airflow limitation, chronic inflammation, recurrent exacerbations, and progressive impairment of pulmonary function.
Breathe Biologics is pursuing a Phase 2 development pathway for JadiCell™ in COPD.
Inflammation & Tissue Injury
Potential areas of biological relevance include immune dysregulation, oxidative injury, epithelial dysfunction, endothelial injury, and chronic inflammatory signaling.
Biological rationale does not establish clinical benefit, and therapeutic activity must be evaluated through appropriately controlled clinical studies.
Areas of Potential Future Pulmonary Evaluation
The following disease areas may be considered for future evaluation based on biological rationale and strategic fit. They are not presented as active JadiCell™ clinical programs.
Pulmonary Fibrosis / ILD
Potential Future Indication. Fibrotic and interstitial pulmonary diseases characterized by progressive scarring, epithelial injury, immune dysregulation, and impaired pulmonary function.
Bronchiectasis
Potential Future Indication. Chronic airway disease associated with infection, inflammation, structural airway injury, and maladaptive remodeling.
Pulmonary Vascular Disease
Potential Future Indication. Pulmonary vascular dysfunction may involve inflammation, endothelial injury, vascular remodeling, and right-ventricular stress.
Important: Pulmonary Fibrosis / ILD, Bronchiectasis, and Pulmonary Vascular Disease are identified only as potential future indications. Their inclusion does not establish an active clinical program, IND authorization, clinical efficacy, or a commitment to initiate development in these disease areas.
Selection Criteria for Future Indications
Future pulmonary-development decisions are intended to be guided by scientific, clinical, regulatory, manufacturing, and strategic considerations.
Medical Affairs qualification: The inclusion of a disease on this platform map indicates an area of current development or potential future evaluation as specifically identified above. It does not establish regulatory authorization, clinical efficacy, or superiority over existing therapy.